As of 2025-02-13, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (18.25) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.78 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -307.8%.
The range of the Relative Valuation is (19.37) - (20.56) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
Range | Selected | |
Trailing P/E multiples | 16.5x - 38.8x | 27.6x |
Forward P/E multiples | 32.4x - 34.4x | 33.4x |
Fair Price | (19.37) - (20.56) | (18.25) |
Upside | -320.6% - -334.2% | -307.8% |
Date | P/E |
2025-02-12 | -14.69 |
2025-02-11 | -15.04 |
2025-02-10 | -14.44 |
2025-02-07 | -14.59 |
2025-02-06 | -14.60 |
2025-02-05 | -14.40 |
2025-02-04 | -13.53 |
2025-02-03 | -12.75 |
2025-01-31 | -13.22 |
2025-01-30 | -13.17 |
2025-01-29 | -13.42 |
2025-01-28 | -13.27 |
2025-01-27 | -13.40 |
2025-01-24 | -12.78 |
2025-01-23 | -12.93 |
2025-01-22 | -12.75 |
2025-01-21 | -12.73 |
2025-01-17 | -12.46 |
2025-01-16 | -11.81 |
2025-01-15 | -12.09 |
2025-01-14 | -12.09 |
2025-01-13 | -13.27 |
2025-01-10 | -12.83 |
2025-01-08 | -13.47 |
2025-01-07 | -13.62 |
2025-01-06 | -13.10 |
2025-01-03 | -12.88 |
2025-01-02 | -13.10 |
2024-12-31 | -12.58 |
2024-12-30 | -12.60 |
2024-12-27 | -12.90 |
2024-12-26 | -12.91 |
2024-12-24 | -12.83 |
2024-12-23 | -13.01 |
2024-12-20 | -12.66 |
2024-12-19 | -12.36 |
2024-12-18 | -12.23 |
2024-12-17 | -12.53 |
2024-12-16 | -12.48 |
2024-12-13 | -12.60 |
2024-12-12 | -12.71 |
2024-12-11 | -13.15 |
2024-12-10 | -13.27 |
2024-12-09 | -12.93 |
2024-12-06 | -12.73 |
2024-12-05 | -13.12 |
2024-12-04 | -12.26 |
2024-12-03 | -12.03 |
2024-12-02 | -12.35 |
2024-11-29 | -12.55 |